Article tools
Author information

Research Article

Tyrphostin AG 556 improves survival and reduces multiorgan failure in canine Escherichia coli peritonitis.

J E Sevransky, G Shaked, A Novogrodsky, A Levitzki, A Gazit, A Hoffman, R J Elin, Z M Quezado, B D Freeman, P Q Eichacker, R L Danner, S M Banks, J Bacher, M L Thomas, 3rd and C Natanson

Department of Critical Care Medicine, National Institutes of Health, Bethesda, Maryland 20892, USA. jsevransky@nih.gov

Published April 15, 1997

Tyrosine kinase-dependent cell signaling is postulated to be a pivotal control point in inflammatory responses initiated by bacterial products and TNF. Using a canine model of gram-negative septic shock, we investigated the effect of tyrosine kinase inhibitors (tyrphostins) on survival. Animals were infected intraperitoneally with Escherichia coli 0111: B4, and then, in a randomized, blinded fashion, were treated immediately with one of two tyrphostins, AG 556 (n = 40) or AG 126 (n = 10), or with control (n = 50), and followed for 28 d or until death. All animals received supplemental oxygen, fluids, and antibiotics. Tyrphostin AG 556 improved survival times when compared to controls (P = 0.05). During the first 48 h after infection, AG 556 also improved mean arterial pressure, left ventricular ejection fraction, cardiac output, oxygen delivery, and alveolar-arterial oxygen gradient compared to controls (all P < or = 0.05). These improvements in organ injury were significantly predictive of survival. Treatment with AG 556 had no effect on clearance of endotoxin or bacteria from the blood (both P = NS); however, AG 556 did significantly lower serum TNF levels (P = 0.03). These data are consistent with the conclusion that AG 556 prevented cytokine-induced multiorgan failure and death during septic shock by inhibiting cell-signaling pathways without impairing host defenses as determined by clearance of bacteria and endotoxin.

Articles that cite
this article:

Tyrphostin AG 126 reduces intestinal ischemia-reperfusion injury in the rat
Stefania Marzocco, Emanuela Mazzon, Aldo Pinto, Giuseppina Autore, Salvatore Cuzzocrea
naunyn-schmiedeberg&apos s arch pharmacol 372(5):362. [CrossRef]

Can we learn from the pathogenetic strategies of group A hemolytic streptococci how tissues are injured and organs fail in post-infectious and inflammatory sequelae?
Isaac Ginsburg, Peter A Ward, James Varani
FEMS Immunol Med Microbiol 25(4):325. [CrossRef]

Novel therapies for sepsis: antiendotoxin therapies
Sanjay Manocha, Daniel Feinstein, Aseem Kumar, Anand Kumar
Expert Opin Invest Drugs 11(12):1795. [CrossRef]


Doraid Jarrar, Ping Wang, Grace Song, William Cioffi, Kirby Bland, Irshad Chaudry
Ann Surg 231(3):399. [CrossRef]

The tyrosine kinase inhibitor tyrphostin AG126 reduces renal ischemia/reperfusion injury in the rat
Prabal K. Chatterjee, Nimesh S.A. Patel, Espen O. Kvale, Paul A.J. Brown, Keith N. Stewart, Domenico Britti, Salvatore Cuzzocrea, Helder Mota-filipe, Christoph Thiemermann
Kidney Int 64(5):1605. [CrossRef]

Sepsis: current status, future prospects
John C Marshall
Curr Opin Crit Care 10(4):250. [CrossRef]

Multi-drug strategies are necessary to inhibit the synergistic mechanism causing tissue damage and organ failure in post infectious sequelae
Isaac Ginsburg
Inflammopharmacol 7(3):207. [CrossRef]